Morphic (MORF) Stock Forecast, Price Target & Predictions
MORF Stock Forecast
Morphic stock forecast is as follows: an average price target of $57.00 (represents a 0.02% upside from MORF’s last price of $56.99) and a rating consensus of 'Hold', based on 6 wall street analysts offering a 1-year stock forecast.
MORF Price Target
The average price target for Morphic (MORF) is $57.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $57.00. This represents a potential 0.02% upside from MORF's last price of $56.99.
MORF Analyst Ratings
According to 6 Wall Street analysts, Morphic's rating consensus is 'Hold'. The analyst rating breakdown for MORF stock is 0 'Strong Buy' (0.00%), 1 'Buy' (16.67%), 5 'Hold' (83.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Morphic Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 22, 2024 | Alex Thompson | Stifel Nicolaus | $57.00 | $56.52 | 0.85% | 0.02% |
| Jul 13, 2024 | Michael Yee | Jefferies | $57.00 | $55.78 | 2.19% | 0.02% |
| Jul 08, 2024 | Edward Nash | Canaccord Genuity | $57.00 | $55.74 | 2.26% | 0.02% |
| Mar 13, 2024 | Michael Yee | Jefferies | $60.00 | $34.60 | 73.41% | 5.28% |
The latest Morphic stock forecast, released on Jul 22, 2024 by Alex Thompson from Stifel Nicolaus, set a price target of $57.00, which represents a 0.85% increase from the stock price at the time of the forecast ($56.52), and a 0.02% increase from MORF last price ($56.99).
Morphic Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $57.75 |
| Last Closing Price | $56.99 | $56.99 | $56.99 |
| Upside/Downside | -100.00% | -100.00% | 1.33% |
In the current month, the average price target of Morphic stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Morphic's last price of $56.99. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 13, 2024 | Jefferies | - | Hold | Downgrade |
| Jul 09, 2024 | Cowen & Co. | - | Hold | Downgrade |
| Jul 09, 2024 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Jul 08, 2024 | BMO Capital | - | Market Perform | Downgrade |
| Sep 25, 2023 | Needham | - | Hold | Initialise |
| Feb 25, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Mar 07, 2021 | Wells Fargo | Overweight | Overweight | Hold |
Morphic's last stock rating was published by Jefferies on Jul 13, 2024. The company Downgrade its MORF rating from "null" to "Hold".
Morphic Financial Forecast
Morphic Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $521.00K | $6.13M | $2.06M | $60.24M | $2.38M | $9.56M | $3.12M | $3.85M | $3.27M | $5.90M | $25.76M | $7.69M | $5.59M | $-334.00K | $5.67M | $5.57M |
| Avg Forecast | $750.00K | $250.00K | - | $1.98M | $1.33M | $2.40M | $2.16M | $3.04M | $3.48M | $3.65M | $3.75M | $14.86M | $5.19M | $5.80M | $7.83M | $6.62M | $12.30M | $5.57M | $4.47M | $5.77M | $5.03M | $470.78K |
| High Forecast | $750.00K | $250.00K | - | $2.38M | $1.33M | $2.40M | $2.16M | $3.04M | $3.48M | $3.65M | $3.75M | $14.86M | $5.19M | $5.80M | $7.83M | $6.62M | $12.30M | $5.57M | $4.47M | $5.77M | $5.03M | $564.94K |
| Low Forecast | $750.00K | $250.00K | - | $1.58M | $1.33M | $2.40M | $2.16M | $3.04M | $3.48M | $3.65M | $3.75M | $14.86M | $5.19M | $5.80M | $7.83M | $6.62M | $12.30M | $5.57M | $4.47M | $5.77M | $5.03M | $376.62K |
| # Analysts | 1 | 1 | - | 18 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 8 |
| Surprise % | - | - | - | - | - | - | 0.24% | 2.02% | 0.59% | 16.48% | 0.63% | 0.64% | 0.60% | 0.66% | 0.42% | 0.89% | 2.09% | 1.38% | 1.25% | -0.06% | 1.13% | 11.83% |
Morphic's average Quarter revenue forecast for Jun 23 based on 5 analysts is $2.40M, with a low forecast of $2.40M, and a high forecast of $2.40M. MORF's average Quarter revenue forecast represents a 361.46% increase compared to the company's last Quarter revenue of $521.00K (Mar 23).
Morphic EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 18 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 8 |
| EBITDA | - | - | - | - | $-44.75M | - | $-39.20M | $-26.34M | $-31.24M | $26.60M | $-31.41M | $-20.42M | $-24.72M | $-27.53M | $-21.00M | $-17.51M | $5.75M | $-15.32M | $-15.73M | $-18.15M | $-8.35M | $-9.10M |
| Avg Forecast | $-734.30K | $-244.77K | - | $-25.79M | $-1.31M | $-2.35M | $-27.58M | $-15.59M | $-3.41M | $-3.58M | $-29.50M | $-14.55M | $-5.08M | $-5.68M | $-17.95M | $-6.48M | $-12.04M | $-5.46M | $-13.44M | $-5.65M | $-4.92M | $-80.46M |
| High Forecast | $-734.30K | $-244.77K | - | $-20.63M | $-1.31M | $-2.35M | $-22.07M | $-12.47M | $-3.41M | $-3.58M | $-23.60M | $-14.55M | $-5.08M | $-5.68M | $-14.36M | $-6.48M | $-12.04M | $-5.46M | $-10.75M | $-5.65M | $-4.92M | $-64.37M |
| Low Forecast | $-734.30K | $-244.77K | - | $-30.95M | $-1.31M | $-2.35M | $-33.10M | $-18.71M | $-3.41M | $-3.58M | $-35.40M | $-14.55M | $-5.08M | $-5.68M | $-21.53M | $-6.48M | $-12.04M | $-5.46M | $-16.13M | $-5.65M | $-4.92M | $-96.55M |
| Surprise % | - | - | - | - | 34.28% | - | 1.42% | 1.69% | 9.16% | -7.43% | 1.06% | 1.40% | 4.86% | 4.85% | 1.17% | 2.70% | -0.48% | 2.81% | 1.17% | 3.21% | 1.70% | 0.11% |
3 analysts predict MORF's average Quarter EBITDA for Sep 22 to be $-3.41M, with a high of $-3.41M and a low of $-3.41M. This is -112.82% lower than Morphic's previous annual EBITDA (Jun 22) of $26.60M.
Morphic Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 18 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 8 |
| Net Income | - | - | - | - | $-36.21M | - | $-36.13M | $-24.38M | $-30.02M | $26.84M | $-31.30M | $-21.97M | $-25.04M | $-27.82M | $-21.28M | $-17.75M | $5.35M | $-15.86M | $-16.75M | $-19.83M | $-8.86M | $-9.43M |
| Avg Forecast | $-50.60M | $-46.92M | $-50.10M | $-26.16M | $-47.77M | $-43.69M | $-27.98M | $-16.34M | $-41.58M | $-42.27M | $-29.93M | $-24.63M | $-36.37M | $-27.35M | $-18.19M | $-25.05M | $-21.44M | $-28.05M | $-14.30M | $-20.16M | $-19.91M | $-83.41M |
| High Forecast | $-50.60M | $-40.34M | $-50.10M | $-20.93M | $-41.24M | $-43.69M | $-22.39M | $-13.07M | $-41.58M | $-42.27M | $-23.94M | $-24.63M | $-36.37M | $-27.35M | $-14.55M | $-25.05M | $-21.44M | $-28.05M | $-11.44M | $-20.16M | $-19.91M | $-66.73M |
| Low Forecast | $-50.60M | $-52.62M | $-50.10M | $-31.40M | $-58.34M | $-43.69M | $-33.58M | $-19.60M | $-41.58M | $-42.27M | $-35.92M | $-24.63M | $-36.37M | $-27.35M | $-21.83M | $-25.05M | $-21.44M | $-28.05M | $-17.16M | $-20.16M | $-19.91M | $-100.09M |
| Surprise % | - | - | - | - | 0.76% | - | 1.29% | 1.49% | 0.72% | -0.64% | 1.05% | 0.89% | 0.69% | 1.02% | 1.17% | 0.71% | -0.25% | 0.57% | 1.17% | 0.98% | 0.45% | 0.11% |
Morphic's average Quarter net income forecast for Sep 22 is $-41.58M, with a range of $-41.58M to $-41.58M. MORF's average Quarter net income forecast represents a -254.91% decrease compared to the company's last Quarter net income of $26.84M (Jun 22).
Morphic SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 18 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 8 |
| SG&A | - | - | - | - | $10.38M | - | $9.28M | $8.01M | $8.30M | $8.23M | $7.59M | $7.44M | $7.28M | $7.14M | $5.95M | $5.13M | $4.75M | $4.20M | $4.42M | $3.43M | $2.90M | $2.08M |
| Avg Forecast | $11.61M | $3.87M | - | $30.64M | $20.64M | $37.21M | $33.41M | $47.06M | $53.92M | $56.56M | $58.10M | $230.00M | $80.34M | $89.78M | $5.09M | $102.46M | $190.38M | $86.27M | $3.78M | $89.26M | $77.78M | $7.29M |
| High Forecast | $11.61M | $3.87M | - | $36.77M | $20.64M | $37.21M | $33.41M | $47.06M | $53.92M | $56.56M | $58.10M | $230.00M | $80.34M | $89.78M | $6.10M | $102.46M | $190.38M | $86.27M | $4.53M | $89.26M | $77.78M | $8.74M |
| Low Forecast | $11.61M | $3.87M | - | $24.51M | $20.63M | $37.21M | $33.41M | $47.06M | $53.92M | $56.56M | $58.10M | $230.00M | $80.34M | $89.78M | $4.07M | $102.46M | $190.38M | $86.27M | $3.02M | $89.26M | $77.78M | $5.83M |
| Surprise % | - | - | - | - | 0.50% | - | 0.28% | 0.17% | 0.15% | 0.15% | 0.13% | 0.03% | 0.09% | 0.08% | 1.17% | 0.05% | 0.02% | 0.05% | 1.17% | 0.04% | 0.04% | 0.29% |
Morphic's average Quarter SG&A projection for Mar 24 is $30.64M, based on 18 Wall Street analysts, with a range of $24.51M to $36.77M. The forecast indicates a 195.07% rise compared to MORF last annual SG&A of $10.38M (Sep 23).
Morphic EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | 18 | 8 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 8 |
| EPS | - | - | - | - | $-0.74 | - | $-0.90 | $-0.64 | $-0.78 | $0.70 | $-0.84 | $-0.60 | $-0.69 | $-0.77 | $-0.63 | $-0.58 | $0.18 | $-0.52 | $-0.55 | $-0.66 | $-0.30 | $-4.73 |
| Avg Forecast | $-1.01 | $-0.94 | $-1.00 | $-0.94 | $-0.95 | $-0.87 | $-0.81 | $-0.87 | $-0.83 | $-0.84 | $-0.81 | $-0.49 | $-0.73 | $-0.55 | $-0.55 | $-0.50 | $-0.43 | $-0.56 | $-0.48 | $-0.40 | $-0.40 | $-3.54 |
| High Forecast | $-1.01 | $-0.81 | $-1.00 | $-0.94 | $-0.82 | $-0.87 | $-0.81 | $-0.87 | $-0.83 | $-0.84 | $-0.81 | $-0.49 | $-0.73 | $-0.55 | $-0.55 | $-0.50 | $-0.43 | $-0.56 | $-0.48 | $-0.40 | $-0.40 | $-2.83 |
| Low Forecast | $-1.01 | $-1.05 | $-1.00 | $-0.94 | $-1.16 | $-0.87 | $-0.81 | $-0.87 | $-0.83 | $-0.84 | $-0.81 | $-0.49 | $-0.73 | $-0.55 | $-0.55 | $-0.50 | $-0.43 | $-0.56 | $-0.48 | $-0.40 | $-0.40 | $-4.24 |
| Surprise % | - | - | - | - | 0.78% | - | 1.11% | 0.73% | 0.94% | -0.83% | 1.04% | 1.22% | 0.95% | 1.41% | 1.15% | 1.16% | -0.42% | 0.93% | 1.15% | 1.63% | 0.75% | 1.34% |
According to 3 Wall Street analysts, Morphic's projected average Quarter EPS for Sep 22 is $-0.83, with a low estimate of $-0.83 and a high estimate of $-0.83. This represents a -218.57% decrease compared to MORF previous annual EPS of $0.70 (Jun 22).
Morphic Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.15 | $33.86 | 1474.88% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| PLRX | Pliant Therapeutics | $14.49 | $39.71 | 174.05% | Buy |
| ETNB | 89bio | $9.29 | $22.00 | 136.81% | Buy |
| STOK | Stoke Therapeutics | $13.10 | $30.60 | 133.59% | Buy |
| IMCR | Immunocore | $31.17 | $70.75 | 126.98% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| AKRO | Akero Therapeutics | $32.05 | $46.00 | 43.53% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| RNA | Avidity Biosciences | $44.82 | $54.50 | 21.60% | Buy |
| PCVX | Vaxcyte | $106.49 | $124.14 | 16.57% | Buy |
| PTGX | Protagonist Therapeutics | $46.76 | $50.00 | 6.93% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.87 | $58.57 | 4.83% | Buy |
| MORF | Morphic | $56.99 | $57.00 | 0.02% | Hold |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
| ACLX | Arcellx | $86.44 | $71.57 | -17.20% | Buy |
MORF Forecast FAQ
Is Morphic a good buy?
No, according to 6 Wall Street analysts, Morphic (MORF) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 16.67% of MORF's total ratings.
What is MORF's price target?
Morphic (MORF) average price target is $57 with a range of $57 to $57, implying a 0.02% from its last price of $56.99. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Morphic stock go up soon?
According to Wall Street analysts' prediction for MORF stock, the company can go up by 0.02% (from the last price of $56.99 to the average price target of $57), up by 0.02% based on the highest stock price target, and up by 0.02% based on the lowest stock price target.
Can Morphic stock reach $90?
MORF's average twelve months analyst stock price target of $57 does not support the claim that Morphic can reach $90 in the near future.
What are Morphic's analysts' financial forecasts?
MORF's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.98M (high $3.38M, low $2.58M), average EBITDA is $-26.77M (high $-21.612M, low $-31.928M), average net income is $-174M (high $-162M, low $-185M), average SG&A $46.12M (high $52.25M, low $39.99M), and average EPS is $-3.888 (high $-3.756, low $-4.001).
Did the MORF's actual financial results beat the analysts' financial forecasts?
Based on Morphic's last annual report (Dec 2022), the company's revenue was $70.81M, beating the average analysts forecast of $13.93M by 408.23%. Apple's EBITDA was $-63.396M, beating the average prediction of $-52.079M by 21.73%. The company's net income was $-59.041M, missing the average estimation of $-130M by -54.62%. Apple's SG&A was $32.14M, missing the average forecast of $215.64M by -85.09%. Lastly, the company's EPS was $-1.55, missing the average prediction of $-3.358 by -53.83%. In terms of the last quarterly report (Mar 2023), Morphic's revenue was $521K, missing the average analysts' forecast of $2.16M by -75.87%. The company's EBITDA was $-39.205M, beating the average prediction of $-27.584M by 42.13%. Morphic's net income was $-36.135M, beating the average estimation of $-27.984M by 29.13%. The company's SG&A was $9.28M, missing the average forecast of $33.41M by -72.24%. Lastly, the company's EPS was $-0.9, beating the average prediction of $-0.81 by 11.11%